Saturday, September 6, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Knockout of CD5 on CAR T cells boosts anti-tumor efficacy

July 22, 2024
in Cancer
Reading Time: 6 mins read
0
67
SHARES
610
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center.

PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center.

CAR T cells are T cells that have been engineered to attack specific targets found on cancer cells. They have had remarkable results in some patients with blood cancers. But they have not performed well against other cancers including solid-tumor cancers, such as pancreatic cancer, prostate cancer, and melanoma. Researchers have been searching for techniques to boost the effectiveness of CAR T cell therapy.

The study, published today in Science Immunology, suggests that knocking out CD5 could be a prime technique. Illuminating the protein’s previously murky role, the researchers found that it works as a powerful immune checkpoint, reining in T cell effectiveness. Removing it, they showed, dramatically enhanced CAR T cell anticancer activity in a variety of preclinical cancer models.

“We’ve discovered in preclinical models that CD5 deletion greatly enhances the function of CAR T cells against multiple cancers,” said senior author Marco Ruella, MD, an assistant professor of Hematology-Oncology, researcher with the Center for Cellular Immunotherapies and the scientific director of Penn Medicine’s Lymphoma Program. “The striking effects we observed across preclinical models suggest that CD5 knockout could be a general strategy for enhancing CAR T cell function.”

The study’s first author is Ruchi Patel, PhD, a recent graduate student from the Ruella Laboratory.

Immune checkpoint basics

Immune checkpoint mechanisms are regulatory switches that help keep immune responses from becoming too intense and causing collateral tissue damage. Cancers often hijack these mechanisms to suppress anticancer immune responses.

Scientists have already identified several major immune checkpoint proteins including PD-1 and CTLA-4, which were the targets of the earliest successful immune checkpoint inhibitor therapies, including ipilimumab, nivolumab, and pembrolizumab. While researchers are investigating the genetic deletion of these proteins to enhance CAR T cell therapies, scientists believe there are other, so-far-undiscovered immune checkpoint mechanisms that cancers exploit.

Strategy for focusing on CD5

Before studying the role of CD5 in CAR T cells, the researchers initially focused on CD5 as a tumor target. The CD5 protein is highly expressed on cancerous T cells in T-cell lymphoma and T-cell acute lymphoblastic leukemia, rare blood cancers that do not have effective immunotherapy treatment options. In particular, none of the currently available commercial CAR T cell therapies are approved to treat T-cell lymphomas.

Ruella’s team first engineered CAR T cells that target CD5-bearing cells to treat these malignancies but soon realized that they needed to delete CD5 in CAR T cells to prevent the CAR T cells from killing each other since the CAR T cells naturally express CD5. Therefore, using CRISPR-Cas9 technology, they deleted the CD5 gene in CAR T cells, so the engineered cells wouldn’t attack each other. This knockout of CD5 in the CAR T cells turned out to provide a dramatic boost to their effectiveness in lab experiments with a variety of T-cell malignancies.

However, the researchers soon realized that CD5 deletion was able to broadly enhance the anti-tumor effect of multiple CAR T products for both liquid and solid cancers. The researchers found similar improvements in effectiveness in laboratory studies when they tested the CD5-knockout strategy in CAR T cells engineered to target other, non-CD5-bearing cancers including B-cell leukemias and lymphomas, pancreatic cancer and prostate cancer. They observed increases in proliferation and survival of the CAR T cells as well as increased cancer-cell-killing activity, and these effects surpassed those observed after the knockout of the known immune checkpoint protein PD-1. The researchers also found that CD5 knockout could improve the anticancer activity of other T cells, again suggesting that CD5 is an important immune checkpoint protein in these cells.

In the study, the team detailed the molecular mechanisms of CD5 knockout, showing that it enhances the activities of genes relating to T cell activation and cell-killing effectiveness. Analyzing a large database of tumor biopsies, the investigators also linked relatively low CD5 expression in T cells to better patient outcomes.

Research moves into clinical trial

A Phase I clinical trial of CD5-knockout CAR T cells will soon begin enrolling patients with CD5-bearing T-cell lymphomas. “If the CD5-knockout strategy is safe and effective in such trials, it could be tested against a wider range of cancers,” Ruella said. “We’re excited to see this work move ‘from bench to bedside’.”

For more information about cancer clinical trials at Penn Medicine, visit the Abramson Cancer Center Clinical Trial Information Service website or call 1-855-216-0098 to speak to a clinical trial navigator.

The research was supported by funding from the National Institutes of Health and National Cancer Institute (R37-CA-262362-02), Leukemia and Lymphoma Society, Gilead Research Scholar Award in Hematology, Emerson Collective, Laffey McHugh Foundation, Parker Institute for Cancer Immunotherapy, Berman and Maguire Funds for Lymphoma Research at Penn, American Society of Hematology, and viTToria Biotherapeutics.

Editor’s Note: Ruella is the scientific founder of, a paid consultant for, and an equity holder in, ViTToria Biotherapeutics. The University of Pennsylvania holds equity in ViTToria Biotherapeutics, has received sponsored research funding from ViTToria, has licensed certain intellectual property to Vittoria and may receive future research funding and financial consideration based on development and commercialization of certain products by ViTToria. Patel is now an employee of ViTToria Biotherapeutics.

###

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.



Journal

Science Immunology

DOI

10.1126/sciimmunol.adn6509

Article Title

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Article Publication Date

19-Jul-2024

Share27Tweet17
Previous Post

Even in ‘care work,’ women face lower wages if they have kids

Next Post

Not everything that tastes bitter is potentially harmful. But why? Study provides an explanation

Related Posts

Cancer

Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients

September 6, 2025
blank
Cancer

Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC

September 6, 2025
blank
Cancer

COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC

September 6, 2025
blank
Cancer

Study Confirms Accuracy of AI Lung Cancer Risk Model Sybil in Predominantly Black Patients at Urban Safety-Net Hospital

September 6, 2025
blank
Cancer

Microbiome’s Hidden Role in Early Tumor Development

September 6, 2025
blank
Cancer

Natural Medicines Target Tumor Blood Vessels to Halt Cancer Progression

September 5, 2025
Next Post
Principal investigator PD Dr. Maik Behrens and doctoral student Silvia Schäfer in the office

Not everything that tastes bitter is potentially harmful. But why? Study provides an explanation

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27544 shares
    Share 11014 Tweet 6884
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    960 shares
    Share 384 Tweet 240
  • Bee body mass, pathogens and local climate influence heat tolerance

    643 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    510 shares
    Share 204 Tweet 128
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    313 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Exploring Finnish Parents’ Faith After Child Loss
  • Exploring Nurses’ Insights on Employee Assistance Programs
  • Assessing Student Social-Emotional-BEHavioral Risk Factors
  • Reemployment Opportunities for Older Workers in China

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,183 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading